JP4543344B2 - フェニルピラゾール誘導体 - Google Patents

フェニルピラゾール誘導体 Download PDF

Info

Publication number
JP4543344B2
JP4543344B2 JP2009541174A JP2009541174A JP4543344B2 JP 4543344 B2 JP4543344 B2 JP 4543344B2 JP 2009541174 A JP2009541174 A JP 2009541174A JP 2009541174 A JP2009541174 A JP 2009541174A JP 4543344 B2 JP4543344 B2 JP 4543344B2
Authority
JP
Japan
Prior art keywords
phenyl
propoxy
methylpyrrolidin
pyrazol
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009541174A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2009063953A1 (ja
Inventor
年男 中村
誠 田続
大 野沢
智子 民田
誠治 増田
裕之 太田
修平 柏
彩 藤野
茂之 茶木
聡立 島▲崎▼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taisho Pharmaceutical Co Ltd
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of JP4543344B2 publication Critical patent/JP4543344B2/ja
Publication of JPWO2009063953A1 publication Critical patent/JPWO2009063953A1/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2009541174A 2007-11-13 2008-11-13 フェニルピラゾール誘導体 Expired - Fee Related JP4543344B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2007294040 2007-11-13
JP2007294040 2007-11-13
JP2008153736 2008-06-12
JP2008153736 2008-06-12
PCT/JP2008/070712 WO2009063953A1 (ja) 2007-11-13 2008-11-13 フェニルピラゾール誘導体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010024303A Division JP5375639B2 (ja) 2007-11-13 2010-02-05 フェニルピラゾール誘導体

Publications (2)

Publication Number Publication Date
JP4543344B2 true JP4543344B2 (ja) 2010-09-15
JPWO2009063953A1 JPWO2009063953A1 (ja) 2011-03-31

Family

ID=40638800

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009541174A Expired - Fee Related JP4543344B2 (ja) 2007-11-13 2008-11-13 フェニルピラゾール誘導体
JP2010024303A Expired - Fee Related JP5375639B2 (ja) 2007-11-13 2010-02-05 フェニルピラゾール誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010024303A Expired - Fee Related JP5375639B2 (ja) 2007-11-13 2010-02-05 フェニルピラゾール誘導体

Country Status (24)

Country Link
US (3) US7888354B2 (enExample)
EP (1) EP2221298B1 (enExample)
JP (2) JP4543344B2 (enExample)
KR (1) KR101571176B1 (enExample)
CN (1) CN101855211B (enExample)
AU (1) AU2008321823B2 (enExample)
BR (1) BRPI0820432B8 (enExample)
CA (1) CA2705502C (enExample)
CY (1) CY1114877T1 (enExample)
DK (1) DK2221298T3 (enExample)
ES (1) ES2436146T3 (enExample)
HR (1) HRP20131060T1 (enExample)
IL (2) IL205509A (enExample)
MX (1) MX2010005225A (enExample)
MY (1) MY173546A (enExample)
NZ (1) NZ585661A (enExample)
PH (1) PH12012501917A1 (enExample)
PL (1) PL2221298T3 (enExample)
PT (1) PT2221298E (enExample)
RS (1) RS53125B (enExample)
RU (1) RU2480456C2 (enExample)
SI (1) SI2221298T1 (enExample)
WO (1) WO2009063953A1 (enExample)
ZA (1) ZA201003111B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010143943A (ja) * 2007-11-13 2010-07-01 Taisho Pharmaceutical Co Ltd フェニルピラゾール誘導体
JP2010285423A (ja) * 2009-05-12 2010-12-24 Taisho Pharmaceutical Co Ltd フェニルピラゾール誘導体

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100113776A1 (en) * 2006-12-14 2010-05-06 Taisho Pharmaceutical Co.,Ltd. Pyrazole derivative
BR112014013461A2 (pt) * 2011-12-08 2017-06-13 Taisho Pharmaceutical Co Ltd derivado de fenilpirrol
WO2013100054A1 (ja) 2011-12-27 2013-07-04 大正製薬株式会社 フェニルトリアゾール誘導体
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
EP2928474B1 (en) 2012-12-07 2018-11-14 ChemoCentryx, Inc. Diazole lactams
WO2014111356A1 (en) * 2013-01-17 2014-07-24 F. Hoffmann-La Roche Ag Oxytocin receptor agonists for the treatment of cns diseases
IL261998B2 (en) 2016-04-07 2023-03-01 Chemocentryx Inc Reducing your burden by giving ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002040461A2 (en) * 2000-11-17 2002-05-23 Abbott Laboratories Aminoalkoxybiphenyl carboxamides as histamine-3 receptor ligands and their therapeutic applications
WO2006059778A1 (ja) * 2004-12-01 2006-06-08 Banyu Pharmaceutical Co., Ltd. 置換ピリドン誘導体
WO2006103057A1 (en) * 2005-03-31 2006-10-05 Ucb Pharma, S.A. Compounds comprising an oxazoline or thiazoline moiety, processes for making them, and their uses
WO2007009741A1 (en) * 2005-07-19 2007-01-25 Glaxo Group Limited Piperazinone derivatives useful as histamine h3 receptor antagonists and/or inverse agonists
WO2007009739A1 (en) * 2005-07-19 2007-01-25 Glaxo Group Limited Compounds
WO2007094962A2 (en) * 2006-02-09 2007-08-23 Athersys, Inc. Pyrazoles for the treatment of obesity and other cns disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104311A (en) * 1992-02-05 1997-07-13 Fujisawa Pharmaceutical Co Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
CZ2003686A3 (cs) 2000-08-08 2003-08-13 Ortho Mcneil Pharmaceutical, Inc. Neimidazolové aryloxypiperidiny
JP4612990B2 (ja) * 2001-03-16 2011-01-12 アボット・ラボラトリーズ ヒスタミン−３受容体リガンドとしての新規アミンおよびそれらの治療的適用
US7595316B2 (en) 2003-06-27 2009-09-29 Banyu Pharmaceutical Co., Ltd. Heteroaryloxy nitrogenous saturated heterocyclic derivative
JP2007531753A (ja) 2004-03-31 2007-11-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 非イミダゾール系複素環式化合物
GB0408083D0 (en) 2004-04-08 2004-05-12 Glaxo Group Ltd Novel compounds
FR2870846B1 (fr) 2004-05-25 2006-08-04 Sanofi Synthelabo Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
SE0401971D0 (sv) 2004-08-02 2004-08-02 Astrazeneca Ab Piperidne derivatives
EP1784400B1 (en) 2004-08-23 2015-01-14 Eli Lilly And Company Histamine h3 receptor agents, preparation and therapeutic uses
BRPI0518222A (pt) 2004-10-19 2008-11-04 Hoffmann La Roche composto, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3 e utilização dos mesmos
WO2006046131A1 (en) 2004-10-29 2006-05-04 Pfizer Products Inc. Tetralin histamine-3 receptor antagonists
BRPI0518841A2 (pt) 2004-12-07 2008-12-09 Glaxo Group Ltd derivados de indenila e uso destes para o tratamento de transtornos neurolàgicos
CN101151244B (zh) 2005-04-01 2014-09-03 伊莱利利公司 组胺h3受体活性剂、制备和治疗用途
DE102005033448A1 (de) * 2005-07-18 2007-01-25 Josef Gail Druckgas-Zylinderläufermotor
US20100113776A1 (en) 2006-12-14 2010-05-06 Taisho Pharmaceutical Co.,Ltd. Pyrazole derivative
EP2134673A1 (en) * 2007-04-12 2009-12-23 DSM Fine Chemicals Austria Nfg GmbH & Co KG Improved process for preparing o-chloromethylphenylglyoxylic esters, improved process for preparing (e)-2-(2-chloromethylphenyl)-2-alkoximinoacetic esters, and novel intermediates for their preparation
CN101855211B (zh) * 2007-11-13 2013-06-12 大正制药株式会社 苯基吡唑衍生物

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002040461A2 (en) * 2000-11-17 2002-05-23 Abbott Laboratories Aminoalkoxybiphenyl carboxamides as histamine-3 receptor ligands and their therapeutic applications
WO2006059778A1 (ja) * 2004-12-01 2006-06-08 Banyu Pharmaceutical Co., Ltd. 置換ピリドン誘導体
WO2006103057A1 (en) * 2005-03-31 2006-10-05 Ucb Pharma, S.A. Compounds comprising an oxazoline or thiazoline moiety, processes for making them, and their uses
WO2006103045A1 (en) * 2005-03-31 2006-10-05 Ucb Pharma S.A. Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses
WO2007009741A1 (en) * 2005-07-19 2007-01-25 Glaxo Group Limited Piperazinone derivatives useful as histamine h3 receptor antagonists and/or inverse agonists
WO2007009739A1 (en) * 2005-07-19 2007-01-25 Glaxo Group Limited Compounds
WO2007094962A2 (en) * 2006-02-09 2007-08-23 Athersys, Inc. Pyrazoles for the treatment of obesity and other cns disorders

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010143943A (ja) * 2007-11-13 2010-07-01 Taisho Pharmaceutical Co Ltd フェニルピラゾール誘導体
JP2010285423A (ja) * 2009-05-12 2010-12-24 Taisho Pharmaceutical Co Ltd フェニルピラゾール誘導体

Also Published As

Publication number Publication date
US20100267687A1 (en) 2010-10-21
PH12012501917A1 (en) 2014-10-17
PL2221298T3 (pl) 2014-05-30
SI2221298T1 (sl) 2013-12-31
IL205509A0 (en) 2010-12-30
US8183387B2 (en) 2012-05-22
CN101855211B (zh) 2013-06-12
MY173546A (en) 2020-02-04
MX2010005225A (es) 2010-05-27
AU2008321823B2 (en) 2013-03-07
JPWO2009063953A1 (ja) 2011-03-31
EP2221298A4 (en) 2011-09-21
US20110065668A1 (en) 2011-03-17
EP2221298A1 (en) 2010-08-25
RU2480456C2 (ru) 2013-04-27
DK2221298T3 (da) 2013-11-18
CA2705502C (en) 2016-01-26
IL236083A0 (en) 2015-01-29
RS53125B (sr) 2014-06-30
AU2008321823A1 (en) 2009-05-22
BRPI0820432A2 (pt) 2015-05-26
PT2221298E (pt) 2013-12-03
JP5375639B2 (ja) 2013-12-25
ZA201003111B (en) 2011-08-31
IL205509A (en) 2015-09-24
US7888354B2 (en) 2011-02-15
RU2010123924A (ru) 2011-12-20
WO2009063953A1 (ja) 2009-05-22
EP2221298B1 (en) 2013-11-06
HK1145834A1 (en) 2011-05-06
CA2705502A1 (en) 2009-05-22
IL236083A (en) 2016-12-29
CN101855211A (zh) 2010-10-06
ES2436146T3 (es) 2013-12-27
NZ585661A (en) 2012-04-27
US20110065667A1 (en) 2011-03-17
US8193176B2 (en) 2012-06-05
JP2010143943A (ja) 2010-07-01
BRPI0820432B1 (pt) 2020-01-14
CY1114877T1 (el) 2016-12-14
KR101571176B1 (ko) 2015-11-23
HRP20131060T1 (hr) 2013-12-20
KR20100083795A (ko) 2010-07-22
BRPI0820432B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
JP5375639B2 (ja) フェニルピラゾール誘導体
AU2004228120B2 (en) Substituted pyrazoles
US20100113776A1 (en) Pyrazole derivative
CN101395139A (zh) 西格玛受体化合物
JP6098892B2 (ja) フェニルピロール誘導体
CA2521199A1 (en) Pyrazole compounds
JP5740838B2 (ja) フェニルピラゾール誘導体
JP2010090067A (ja) 含窒素複素環誘導体
HK1145834B (en) Phenylpyrazole derivatives
JPWO2013100054A1 (ja) フェニルトリアゾール誘導体
JP2010090075A (ja) インドール又はインドリン誘導体
JP2015027999A (ja) フェニルトリアゾール誘導体を含有する医薬
JP2015013853A (ja) フェニルピロール誘導体を含有する医薬
HK1228379A1 (en) Morpholin-pyridine derivatives

Legal Events

Date Code Title Description
TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100603

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100616

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130709

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4543344

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130709

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees